AU2002232177B2 - Method of detecting nucleotide polymorphism - Google Patents
Method of detecting nucleotide polymorphism Download PDFInfo
- Publication number
- AU2002232177B2 AU2002232177B2 AU2002232177A AU2002232177A AU2002232177B2 AU 2002232177 B2 AU2002232177 B2 AU 2002232177B2 AU 2002232177 A AU2002232177 A AU 2002232177A AU 2002232177 A AU2002232177 A AU 2002232177A AU 2002232177 B2 AU2002232177 B2 AU 2002232177B2
- Authority
- AU
- Australia
- Prior art keywords
- primer
- precursor
- base
- nucleotide
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000003729 nucleotide group Chemical group 0.000 title claims description 305
- 239000002773 nucleotide Substances 0.000 title claims description 287
- 238000000034 method Methods 0.000 title claims description 136
- 230000037429 base substitution Effects 0.000 claims description 129
- 108020004707 nucleic acids Proteins 0.000 claims description 126
- 102000039446 nucleic acids Human genes 0.000 claims description 126
- 150000007523 nucleic acids Chemical class 0.000 claims description 126
- 108010042407 Endonucleases Proteins 0.000 claims description 56
- 102100031780 Endonuclease Human genes 0.000 claims description 55
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 50
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 50
- 239000002243 precursor Substances 0.000 claims description 45
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 38
- 238000003776 cleavage reaction Methods 0.000 claims description 37
- 230000007017 scission Effects 0.000 claims description 36
- 230000003321 amplification Effects 0.000 claims description 31
- 239000012634 fragment Substances 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 27
- 102100034343 Integrase Human genes 0.000 claims description 26
- 101710203526 Integrase Proteins 0.000 claims description 26
- 239000000126 substance Substances 0.000 claims description 22
- 238000006467 substitution reaction Methods 0.000 claims description 22
- 108700028369 Alleles Proteins 0.000 claims description 19
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 17
- 238000000137 annealing Methods 0.000 claims description 15
- 108091028664 Ribonucleotide Proteins 0.000 claims description 14
- 239000002336 ribonucleotide Substances 0.000 claims description 14
- 108091008146 restriction endonucleases Proteins 0.000 claims description 12
- 101710163270 Nuclease Proteins 0.000 claims description 11
- 230000009471 action Effects 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 238000012986 modification Methods 0.000 claims description 10
- 230000004048 modification Effects 0.000 claims description 10
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 6
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 6
- 238000006073 displacement reaction Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000010791 quenching Methods 0.000 claims description 5
- 230000000171 quenching effect Effects 0.000 claims description 5
- 238000002875 fluorescence polarization Methods 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 description 85
- 239000013615 primer Substances 0.000 description 77
- 238000006243 chemical reaction Methods 0.000 description 73
- 238000001514 detection method Methods 0.000 description 52
- 108090000731 ribonuclease HII Proteins 0.000 description 50
- 239000000047 product Substances 0.000 description 39
- 239000000523 sample Substances 0.000 description 39
- 239000011541 reaction mixture Substances 0.000 description 35
- 108091034117 Oligonucleotide Proteins 0.000 description 28
- 239000000243 solution Substances 0.000 description 24
- 102000004190 Enzymes Human genes 0.000 description 23
- 108090000790 Enzymes Proteins 0.000 description 23
- 229940088598 enzyme Drugs 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 22
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 21
- 239000013612 plasmid Substances 0.000 description 20
- 238000001962 electrophoresis Methods 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 17
- 239000005547 deoxyribonucleotide Substances 0.000 description 17
- -1 aminohexyl Chemical group 0.000 description 16
- 108020004705 Codon Proteins 0.000 description 14
- 239000011543 agarose gel Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 239000000872 buffer Substances 0.000 description 13
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 230000000692 anti-sense effect Effects 0.000 description 12
- 241000205042 Archaeoglobus fulgidus Species 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 230000004544 DNA amplification Effects 0.000 description 8
- 241000205156 Pyrococcus furiosus Species 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 101000919361 Homo sapiens Cytochrome P450 2C19 Proteins 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 239000008223 sterile water Substances 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102000019057 Cytochrome P-450 CYP2C19 Human genes 0.000 description 4
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 4
- 239000003155 DNA primer Substances 0.000 description 4
- 108060002716 Exonuclease Proteins 0.000 description 4
- 101710113436 GTPase KRas Proteins 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 102000013165 exonuclease Human genes 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 102000054765 polymorphisms of proteins Human genes 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 3
- 102100030708 GTPase KRas Human genes 0.000 description 3
- 229930010555 Inosine Natural products 0.000 description 3
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 3
- 241000522615 Pyrococcus horikoshii Species 0.000 description 3
- 108091034057 RNA (poly(A)) Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
- 229950006790 adenosine phosphate Drugs 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 238000005251 capillar electrophoresis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000011874 heated mixture Substances 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 229960003786 inosine Drugs 0.000 description 3
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 3
- 239000011654 magnesium acetate Substances 0.000 description 3
- 235000011285 magnesium acetate Nutrition 0.000 description 3
- 229940069446 magnesium acetate Drugs 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 235000011056 potassium acetate Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 108020001019 DNA Primers Proteins 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000203353 Methanococcus Species 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 241000589596 Thermus Species 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 102000057376 human CYP2C19 Human genes 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000002205 phenol-chloroform extraction Methods 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- MKKDSIYTXTZFAU-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;5-methyl-1h-pyrimidine-2,4-dione Chemical compound CC1=CNC(=O)NC1=O.O=C1NC(N)=NC2=C1NC=N2 MKKDSIYTXTZFAU-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000205046 Archaeoglobus Species 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 101900234631 Escherichia coli DNA polymerase I Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000205160 Pyrococcus Species 0.000 description 1
- 101150040459 RAS gene Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 241000205180 Thermococcus litoralis Species 0.000 description 1
- 241000204652 Thermotoga Species 0.000 description 1
- 241000204666 Thermotoga maritima Species 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 241000193758 [Bacillus] caldotenax Species 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 238000007281 aminoalkylation reaction Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 108010041758 cleavase Proteins 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940048084 pyrophosphate Drugs 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003290 ribose derivatives Chemical class 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
- C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001039268 | 2001-02-15 | ||
| JP2001-39268 | 2001-02-15 | ||
| JP2001-40721 | 2001-02-16 | ||
| JP2001040721 | 2001-02-16 | ||
| JP2001101055 | 2001-03-30 | ||
| JP2001-101055 | 2001-03-30 | ||
| JP2001177381 | 2001-06-12 | ||
| JP2001-177381 | 2001-06-12 | ||
| JP2001290384 | 2001-09-25 | ||
| JP2001-290384 | 2001-09-25 | ||
| JP2001338440 | 2001-11-02 | ||
| JP2001-338440 | 2001-11-02 | ||
| JP2001-368929 | 2001-12-03 | ||
| JP2001368929 | 2001-12-03 | ||
| PCT/JP2002/001222 WO2002064833A1 (en) | 2001-02-15 | 2002-02-14 | Method of detecting nucleotide polymorphism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002232177A1 AU2002232177A1 (en) | 2003-02-20 |
| AU2002232177B2 true AU2002232177B2 (en) | 2006-11-09 |
Family
ID=27567022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002232177A Ceased AU2002232177B2 (en) | 2001-02-15 | 2002-02-14 | Method of detecting nucleotide polymorphism |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7135291B2 (https=) |
| EP (1) | EP1367136A4 (https=) |
| JP (3) | JP3681729B2 (https=) |
| KR (1) | KR100809949B1 (https=) |
| CN (1) | CN100351393C (https=) |
| AU (1) | AU2002232177B2 (https=) |
| CA (1) | CA2438574C (https=) |
| EA (1) | EA005141B1 (https=) |
| WO (1) | WO2002064833A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200404889A (en) * | 2002-05-31 | 2004-04-01 | Takara Bio Inc | Method of typing gene polymorphisms |
| ES2393318T3 (es) * | 2005-06-23 | 2012-12-20 | Keygene N.V. | Estrategias para la identificación y detección de alto rendimiento de polimorfismos |
| US10227641B2 (en) | 2008-04-30 | 2019-03-12 | Integrated Dna Technologies, Inc. | RNase H-based assays utilizing modified RNA monomers |
| US8911948B2 (en) * | 2008-04-30 | 2014-12-16 | Integrated Dna Technologies, Inc. | RNase H-based assays utilizing modified RNA monomers |
| WO2014143228A1 (en) * | 2013-03-15 | 2014-09-18 | Integrated Dna Technologies, Inc. | Rnase h-based assays utilizing modified rna monomers |
| US9434988B2 (en) | 2008-04-30 | 2016-09-06 | Integrated Dna Technologies, Inc. | RNase H-based assays utilizing modified RNA monomers |
| DK2279263T3 (da) | 2008-04-30 | 2013-11-11 | Integrated Dna Tech Inc | Rnase-h-baserede assays med anvendelse af modificerede rna-monomerer |
| JPWO2010026933A1 (ja) * | 2008-09-03 | 2012-02-02 | タカラバイオ株式会社 | Ｒｎａ検出用組成物 |
| ES2527653T3 (es) | 2008-10-20 | 2015-01-28 | F. Hoffmann-La Roche Ag | Amplificación específica de alelo usando un cebador con un nucleótido modificado |
| WO2011060014A1 (en) * | 2009-11-13 | 2011-05-19 | Integrated Dna Technologies, Inc. | Small rna detection assays |
| US9238832B2 (en) | 2009-12-11 | 2016-01-19 | Roche Molecular Systems, Inc. | Allele-specific amplification of nucleic acids |
| US8614071B2 (en) | 2009-12-11 | 2013-12-24 | Roche Molecular Systems, Inc. | Preferential amplification of mRNA over DNA using chemically modified primers |
| CA2881200A1 (en) | 2012-02-14 | 2013-08-22 | Great Basin Scientific | Methods of isothermal amplification using blocked primers |
| CN105189746B (zh) | 2013-03-14 | 2018-12-04 | 宝生物工程株式会社 | 用于使用耐热的错配内切核酸酶的方法 |
| CA3207128A1 (en) | 2013-11-14 | 2015-05-21 | Integrated Dna Technologies, Inc. | Dna polymerase mutants having enhanced template discrimination activity |
| EP3825411A1 (en) | 2014-06-18 | 2021-05-26 | Clear Gene, Inc. | Methods, compositions, and devices for rapid analysis of biological markers |
| CN107002067A (zh) | 2014-09-11 | 2017-08-01 | 宝生物工程株式会社 | 利用热稳定性错配内切核酸酶的方法 |
| US9909169B2 (en) | 2014-12-17 | 2018-03-06 | Roche Molecular Systems, Inc. | Allele-specific amplification of nucleic acids using blocking oligonucleotides for wild type suppression |
| JP6914831B2 (ja) * | 2015-03-20 | 2021-08-04 | タカラバイオ株式会社 | 標的核酸の高感度検出方法 |
| WO2017106790A1 (en) | 2015-12-18 | 2017-06-22 | Clear Gene, Inc. | Methods, compositions, kits and devices for rapid analysis of biological markers |
| US12275994B2 (en) | 2017-06-22 | 2025-04-15 | Clear Gene, Inc. | Methods and compositions for the analysis of cancer biomarkers |
| CN108148895A (zh) * | 2017-12-29 | 2018-06-12 | 星阵（广州）基因科技有限公司 | 用于检测突变的人akt1基因的引物、试剂盒及方法 |
| AU2022216246A1 (en) * | 2021-02-02 | 2023-09-14 | Rhodx, Inc. | Synthetic polynucleotides and methods for selectively amplifying alleles |
| CN113215163B (zh) * | 2021-05-12 | 2023-05-12 | 苏州海苗生物科技有限公司 | 一种特异性扩增目的基因的分子锁及应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992002638A1 (en) * | 1990-08-06 | 1992-02-20 | F. Hoffmann-La Roche Ag | Homogeneous assay system |
| WO2001002557A1 (en) * | 1999-06-29 | 2001-01-11 | Janssen Pharmaceutica N.V. | Neurotrophic factor receptor |
| AU7710200A (en) * | 1999-09-22 | 2001-04-24 | Genecopoeia, Inc. | Method and compositions for improved polynucleotide synthesis |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4521509A (en) | 1982-11-24 | 1985-06-04 | Research Corporation | Method for degrading DNA |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5011769A (en) | 1985-12-05 | 1991-04-30 | Meiogenics U.S. Limited Partnership | Methods for detecting nucleic acid sequences |
| US4876187A (en) | 1985-12-05 | 1989-10-24 | Meiogenics, Inc. | Nucleic acid compositions with scissile linkage useful for detecting nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
| JP2650159B2 (ja) | 1988-02-24 | 1997-09-03 | アクゾ・ノベル・エヌ・ベー | 核酸増幅方法 |
| US5639611A (en) * | 1988-12-12 | 1997-06-17 | City Of Hope | Allele specific polymerase chain reaction |
| US5137806A (en) | 1989-12-11 | 1992-08-11 | Board Of Regents, The University Of Texas System | Methods and compositions for the detection of sequences in selected DNA molecules |
| US5455166A (en) | 1991-01-31 | 1995-10-03 | Becton, Dickinson And Company | Strand displacement amplification |
| US5846717A (en) | 1996-01-24 | 1998-12-08 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
| WO1995014106A2 (en) * | 1993-11-17 | 1995-05-26 | Id Biomedical Corporation | Cycling probe cleavage detection of nucleic acid sequences |
| ES2165402T3 (es) * | 1994-07-16 | 2002-03-16 | Roche Diagnostics Gmbh | Procedimiento para la deteccion sensible de acidos nucleicos. |
| ATE414793T1 (de) * | 1996-01-24 | 2008-12-15 | Third Wave Tech Inc | Invasive spaltung von nukleinsäuren |
| NL1002427C2 (nl) * | 1996-02-23 | 1997-08-26 | Akzo Nobel Nv | Bekledingssamenstelling omvattende een bicyclo- of spiroorthoester functionele verbinding. |
| US5808108A (en) * | 1997-01-15 | 1998-09-15 | Chappelow; Cecil C. | Polymeric compositions and composites prepared from spiroorthocarbonates and epoxy monomers |
| DE19733619C1 (de) * | 1997-08-04 | 2000-02-24 | Markus Schuermann | CASE-PCR, ein hochselektives Verfahren zum Nachweis von Onkogenmutationen und Allelvarianten |
| WO2000056877A1 (en) | 1999-03-19 | 2000-09-28 | Takara Shuzo Co., Ltd. | Method for amplifying nucleic acid sequence |
| AU782555B2 (en) | 1999-07-02 | 2005-08-11 | Invitrogen Corporation | Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis |
| GB9918150D0 (en) * | 1999-08-03 | 1999-10-06 | Univ Sheffield | Nuclease variant |
| JP2001136965A (ja) * | 1999-11-12 | 2001-05-22 | Takara Shuzo Co Ltd | 核酸配列の増幅方法 |
| WO2001042498A1 (en) * | 1999-12-10 | 2001-06-14 | Toyo Boseki Kabushiki Kaisha | Method of detecting nucleotide polymorphism |
| EP1356094B1 (en) | 2000-06-26 | 2010-01-13 | Nugen Technologies, Inc. | Methods and compositions for transcription-based nucleic acid amplification |
| US6773885B1 (en) * | 2000-09-29 | 2004-08-10 | Integrated Dna Technologies, Inc. | Compositions and methods for visual ribonuclease detection assays |
| WO2002063049A2 (en) * | 2001-02-02 | 2002-08-15 | Genome Therapeutics Corporation | Methods for determining a nucleotide at a specific location within a nucleic acid molecule |
| AU2002351193A1 (en) * | 2001-11-28 | 2003-06-10 | Mj Bioworks Incorporated | Parallel polymorphism scoring by amplification and error correction |
-
2002
- 2002-02-14 WO PCT/JP2002/001222 patent/WO2002064833A1/ja not_active Ceased
- 2002-02-14 AU AU2002232177A patent/AU2002232177B2/en not_active Ceased
- 2002-02-14 CN CNB028079310A patent/CN100351393C/zh not_active Expired - Fee Related
- 2002-02-14 KR KR1020037010391A patent/KR100809949B1/ko not_active Expired - Fee Related
- 2002-02-14 JP JP2002565143A patent/JP3681729B2/ja not_active Expired - Fee Related
- 2002-02-14 CA CA002438574A patent/CA2438574C/en not_active Expired - Fee Related
- 2002-02-14 EA EA200300880A patent/EA005141B1/ru not_active IP Right Cessation
- 2002-02-14 US US10/468,128 patent/US7135291B2/en not_active Expired - Fee Related
- 2002-02-14 EP EP02712338A patent/EP1367136A4/en not_active Withdrawn
-
2004
- 2004-07-29 JP JP2004221749A patent/JP2004298200A/ja active Pending
-
2005
- 2005-05-17 JP JP2005144399A patent/JP2005245465A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992002638A1 (en) * | 1990-08-06 | 1992-02-20 | F. Hoffmann-La Roche Ag | Homogeneous assay system |
| WO2001002557A1 (en) * | 1999-06-29 | 2001-01-11 | Janssen Pharmaceutica N.V. | Neurotrophic factor receptor |
| AU7710200A (en) * | 1999-09-22 | 2001-04-24 | Genecopoeia, Inc. | Method and compositions for improved polynucleotide synthesis |
Also Published As
| Publication number | Publication date |
|---|---|
| EA005141B1 (ru) | 2004-12-30 |
| EA200300880A1 (ru) | 2004-02-26 |
| CN100351393C (zh) | 2007-11-28 |
| WO2002064833A1 (en) | 2002-08-22 |
| CN1524127A (zh) | 2004-08-25 |
| JPWO2002064833A1 (ja) | 2004-06-17 |
| JP3681729B2 (ja) | 2005-08-10 |
| US20040137451A1 (en) | 2004-07-15 |
| KR20030074797A (ko) | 2003-09-19 |
| CA2438574C (en) | 2009-08-11 |
| EP1367136A1 (en) | 2003-12-03 |
| JP2004298200A (ja) | 2004-10-28 |
| US7135291B2 (en) | 2006-11-14 |
| KR100809949B1 (ko) | 2008-03-06 |
| JP2005245465A (ja) | 2005-09-15 |
| CA2438574A1 (en) | 2002-08-22 |
| EP1367136A4 (en) | 2005-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002232177B2 (en) | Method of detecting nucleotide polymorphism | |
| US6316202B1 (en) | Nucleic acids encoding cold sensitive mutant DNA polymerases | |
| US7056671B2 (en) | Isothermal chimeric primer nucleic acid amplification methods using blocking oglionucleotide | |
| AU704625B2 (en) | Method for characterizing nucleic acid molecules | |
| KR101958659B1 (ko) | 유전자 변이 특이적 증폭 효율이 증가된 dna 중합효소 | |
| JP6579152B2 (ja) | 改変された耐熱性ｄｎａポリメラーゼ | |
| KR101958660B1 (ko) | 유전자 변이 특이성이 증가된 dna 중합효소의 활성 증가용 pcr 버퍼 조성물 | |
| KR20150131146A (ko) | 내열성 미스매치 엔도뉴클레아제의 이용방법 | |
| US20060199178A1 (en) | Method of typing gene polymorphisms | |
| JP4019171B2 (ja) | 誤対合修復系を利用したｄｎａの解析方法および操作方法 | |
| WO2012046140A1 (en) | Enzyme mixture | |
| KR100689795B1 (ko) | 복합체 형성 방법 | |
| JP2024143318A (ja) | メチレンテトラヒドロ葉酸還元酵素の遺伝子多型を検出するためのオリゴヌクレオチドプローブ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |